Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person...

Hello there and happy Friday from STAT’s London outpost, where the weekend is mere hours away. STAT reporter Andrew Joseph here, filling in for Mr. Pharmalot for the day. Spring has fully sprung here in the U.K., and our weekend plans include plenty of park time, and if we’re being honest, likely some time at the pub as well. Wishing you all sunny days...

BALTIMORE — An ambitious effort to cure HIV with CRISPR genome editing fell short in an early clinical trial, investigators announced Friday morning. In the study, run by Excision BioTherapeutics, researchers tried to use the gene editing tool to address a chief reason HIV has been so hard to cure. While antiviral drugs can clear patients of replicating...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hi all. Today we’re talking about improving the global reach of gene therapies, and about why offering access to ancestral populations could be so powerful. We see in a KFF survey that a majority of Americans want obesity drugs...

After seeing its last deal go bust in the face of regulatory scrutiny, Maze Therapeutics has found another suitor for its experimental Pompe disease treatment.  Bay Area-based Maze and Shionogi said Friday that the Japanese pharma company had licensed the drug, called MZE001, with an upfront payment of $150 million. The global deal includes additional,...

LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own.  The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s Covid shot going forward as well as to try to combine the vaccine with Sanofi’s own flu shot. The pact includes a $500 million upfront payment, with up to $700...